Literature DB >> 25368832

Drug holiday as a prognostic factor of medication-related osteonecrosis of the jaw.

Yoon Ho Kim1, Ho Kyung Lee1, Seung Il Song1, Jeong Keun Lee1.   

Abstract

OBJECTIVES: To identify post-treatment prognostic factors for medication-related osteonecrosis of the jaw (MRONJ).
MATERIALS AND METHODS: We evaluated 54 MRONJ patients who visited the Department of Dentistry, Ajou University Hospital, from May 2007 to March 2014. Twenty-one patients were surgically managed with debridement or sequestrectomy and 33 patients were conservatively managed using antibiotics. Correlations of age, sex, stage, bisphosphonate duration and type, and drug holiday with the prognosis of MRONJ were investigated. Correlations were verified by logistic regression analysis and t-tests with a significance level of 0.05.
RESULTS: Clinical outcomes were evaluated on the basis of both clinical and radiographic findings. Twelve out of 21 surgically managed patients showed a favorable prognosis and nine patients relapsed. Thirty-one of the 33 conservatively managed patients showed no specific change in prognosis, and two patients worsened. Statistical analyses of the conservative management group did not reveal any correlation of the above factors with the prognosis of conservative management. Drug holiday was the only prognostic factor in the surgical management group (P=0.031 in logistic regression analysis, P=0.004 in t-test).
CONCLUSION: Drug holiday is a prognostic factor in the surgical management of MRONJ. Because the drug holiday in the patients of the poor prognosis group occurred 1.5 to 4 months prior to surgical management, we recommend a drug holiday more than 4 months before surgery.

Entities:  

Keywords:  Bisphosphonate; Drug holiday; Medication-related osteonecrosis of the jaw; Prognosis

Year:  2014        PMID: 25368832      PMCID: PMC4217272          DOI: 10.5125/jkaoms.2014.40.5.206

Source DB:  PubMed          Journal:  J Korean Assoc Oral Maxillofac Surg        ISSN: 1225-1585


  14 in total

1.  Outcome of treatment and parameters influencing recurrence in patients with bisphosphonate-related osteonecrosis of the jaws.

Authors:  Thomas Mücke; Janett Koschinski; Herbert Deppe; Stefan Wagenpfeil; Christoph Pautke; David A Mitchell; Klaus-Dietrich Wolff; Frank Hölzle
Journal:  J Cancer Res Clin Oncol       Date:  2010-10-07       Impact factor: 4.553

2.  Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management.

Authors:  Salvatore L Ruggiero; John Fantasia; Eric Carlson
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2006-07-31

3.  The outcome after surgical therapy of bisphosphonate-associated osteonecrosis of the jaw--results of a clinical case series with an average follow-up of 20 months.

Authors:  Philipp Stockmann; Moritz Burger; Cornelius von Wilmowsky; Tobias Ebker; Rainer Lutz; Anne Bauersachs; Emeka Nkenke; Friedrich Wilhelm Neukam; Falk Wehrhan
Journal:  Clin Oral Investig       Date:  2013-08-29       Impact factor: 3.573

Review 4.  Management of antiresorptive osteonecrosis of the jaws with primary surgical resection.

Authors:  Eric R Carlson
Journal:  J Oral Maxillofac Surg       Date:  2013-12-15       Impact factor: 1.895

5.  Long-term success of surgery in bisphosphonate-related osteonecrosis of the jaws (BRONJs).

Authors:  Daniel Holzinger; Rudolf Seemann; Clemens Klug; Rolf Ewers; Gabriele Millesi; Arnulf Baumann; Arno Wutzl
Journal:  Oral Oncol       Date:  2012-08-11       Impact factor: 5.337

Review 6.  Treatment of bone diseases with bisphosphonates, excluding osteoporosis.

Authors:  J P Devogelaer
Journal:  Curr Opin Rheumatol       Date:  2000-07       Impact factor: 5.006

7.  Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia.

Authors:  Tony Mavrokokki; Andrew Cheng; Brien Stein; Alastair Goss
Journal:  J Oral Maxillofac Surg       Date:  2007-03       Impact factor: 1.895

8.  Resective surgical approach shows a high performance in the management of advanced cases of bisphosphonate-related osteonecrosis of the jaws: a retrospective survey of 347 cases.

Authors:  Filippo Graziani; Paolo Vescovi; Giuseppina Campisi; Gianfranco Favia; Mario Gabriele; Giovanni Maria Gaeta; Stefano Gennai; Franco Goia; Mario Miccoli; Franco Peluso; Matteo Scoletta; Luigi Solazzo; Giuseppe Colella
Journal:  J Oral Maxillofac Surg       Date:  2012-08-09       Impact factor: 1.895

9.  Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research.

Authors:  Sundeep Khosla; David Burr; Jane Cauley; David W Dempster; Peter R Ebeling; Dieter Felsenberg; Robert F Gagel; Vincente Gilsanz; Theresa Guise; Sreenivas Koka; Laurie K McCauley; Joan McGowan; Marc D McKee; Suresh Mohla; David G Pendrys; Lawrence G Raisz; Salvatore L Ruggiero; David M Shafer; Lillian Shum; Stuart L Silverman; Catherine H Van Poznak; Nelson Watts; Sook-Bin Woo; Elizabeth Shane
Journal:  J Bone Miner Res       Date:  2007-10       Impact factor: 6.741

10.  Bisphosphonates-related osteonecrosis of the jaw in Korea: a preliminary report.

Authors:  Jeong Keun Lee; Kyung-Wook Kim; Jin-Young Choi; Seong-Yong Moon; Su-Gwan Kim; Chul-Hwan Kim; Hyeon-Min Kim; Yong-Dae Kwon; Yong-Deok Kim; Dong-Keun Lee; Seung-Ki Min; In-Sook Park; Young-Wook Park; Min-Suk Kook; Hong-Ju Park; Jin-A Baek; Jun-Woo Park; Tae-Geon Kwon
Journal:  J Korean Assoc Oral Maxillofac Surg       Date:  2013-02-21
View more
  11 in total

1.  Apical surgery in cancer patients receiving high-dose antiresorptive medication-a retrospective clinical study with a mean follow-up of 13 months.

Authors:  Sanne Werner Moeller Andersen; Simon Storgaard Jensen; Morten Schiodt
Journal:  Oral Maxillofac Surg       Date:  2020-09-24

2.  Drug holiday clinical relevance verification for antiresorptive agents in medication-related osteonecrosis cases of the jaw.

Authors:  Saki Hayashida; Souichi Yanamoto; Shigeyuki Fujita; Takumi Hasegawa; Takahide Komori; Yuka Kojima; Hironori Miyamoto; Yasuyuki Shibuya; Nobuhiro Ueda; Tadaaki Kirita; Hirokazu Nakahara; Mitsuyo Shinohara; Eiji Kondo; Hiroshi Kurita; Masahiro Umeda
Journal:  J Bone Miner Metab       Date:  2019-08-13       Impact factor: 2.626

3.  Relationship between drug holiday of the antiresorptive agents and surgical outcome of medication-related osteonecrosis of the jaw in osteoporosis patients.

Authors:  Kota Morishita; Sakiko Soutome; Mitsunobu Otsuru; Saki Hayashida; Maho Murata; Miho Sasaki; Yukinori Takagi; Misa Sumi; Masahiro Umeda
Journal:  Sci Rep       Date:  2022-07-07       Impact factor: 4.996

4.  Impact of communication between physicians and dentists on the incidence of jaw osteonecrosis caused by bone anti-resorptives.

Authors:  Sunday O Akintoye; Elliot V Hersh
Journal:  Curr Med Res Opin       Date:  2016-05-18       Impact factor: 2.580

5.  Value of pre-operative CTX serum levels in the prediction of medication-related osteonecrosis of the jaw (MRONJ): a retrospective clinical study.

Authors:  Martin Salgueiro; Michael Stribos; Li Fang Zhang; Mark Stevens; Mohamed E Awad; Mohammed Elsalanty
Journal:  EPMA J       Date:  2019-01-24       Impact factor: 6.543

Review 6.  Medication Related Osteonecrosis of the Jaw: 2015 Position Statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons.

Authors:  Kyoung Min Kim; Yumie Rhee; Yong-Dae Kwon; Tae-Geon Kwon; Jeong Keun Lee; Deog-Yoon Kim
Journal:  J Bone Metab       Date:  2015-11-30

7.  A critical assessment of the medication-related osteonecrosis of the jaw classification in stage I patients: a retrospective analysis.

Authors:  Oliver Ristow; Lena Hürtgen; Julius Moratin; Maximilian Smielowski; Christian Freudlsperger; Michael Engel; Jürgen Hoffmann; Thomas Rückschloß
Journal:  J Korean Assoc Oral Maxillofac Surg       Date:  2021-04-30

Review 8.  Various Therapeutic Methods for the Treatment of Medication-Related Osteonecrosis of the Jaw (MRONJ) and Their Limitations: A Narrative Review on New Molecular and Cellular Therapeutic Approaches.

Authors:  Sung-Woon On; Seoung-Won Cho; Soo-Hwan Byun; Byoung-Eun Yang
Journal:  Antioxidants (Basel)       Date:  2021-04-27

9.  Medication Related Osteonecrosis of the Jaw: 2021 Position Statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons.

Authors:  Jin-Woo Kim; Mi Kyung Kwak; Jeong Joon Han; Sung-Tak Lee; Ha Young Kim; Se Hwa Kim; Junho Jung; Jeong Keun Lee; Young-Kyun Lee; Yong-Dae Kwon; Deog-Yoon Kim
Journal:  J Bone Metab       Date:  2021-11-30

Review 10.  Medication-Related Osteonecrosis of the Jaw (MRONJ): A Review of Pathophysiology, Risk Factors, Preventive Measures and Treatment Strategies.

Authors:  Raed AlRowis; Abdulmalik Aldawood; Mohammed AlOtaibi; Essam Alnasser; Ibrahim AlSaif; Abdullah Aljaber; Zuhair Natto
Journal:  Saudi Dent J       Date:  2022-01-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.